Show simple item record

dc.contributor.authorAhmed, S Rafeeq
dc.contributor.authorBrooman, P J
dc.contributor.authorShalet, Stephen M
dc.contributor.authorHowell, Anthony
dc.contributor.authorBlacklock, N J
dc.contributor.authorRickards, D
dc.date.accessioned2014-12-22T15:09:41Z
dc.date.available2014-12-22T15:09:41Z
dc.date.issued1983-08-20
dc.identifier.citationTreatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. 1983, 2 (8347):415-9 Lanceten
dc.identifier.issn0140-6736
dc.identifier.pmid6135909
dc.identifier.urihttp://hdl.handle.net/10541/337536
dc.description.abstract9 of 12 patients with advanced metastatic carcinoma of the prostate treated with luteinising-hormone-releasing-hormone (LHRH) analogue ICI 118630 for a mean period of 6 months showed objective evidence of response to treatment. Of 8 patients with bone pain, 7 obtained relief. After 6 weeks of treatment testosterone concentrations were reduced to castrate levels (range less than 2 to 5.5 nmol/l) from a pretreatment mean value of 15.7 nmol/l (range 10.3-24 nmol/l). Basal gonadotropin levels and gonadotropin responses to acute LHRH stimulation were suppressed within 2 weeks of treatment. However, the testosterone response to stimulation with human chorionic gonadotropin was unimpaired 4 weeks after the start of treatment. Therefore suppression of the basal testosterone concentration by ICI 118630 was due to inhibition of pituitary luteinising-hormone secretion rather than direct inhibition of testicular Leydig-cell function. ICI 118630 offers an alternative treatment to orchidectomy and oestrogen therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Lanceten
dc.subject.meshAcid Phosphatase
dc.subject.meshAged
dc.subject.meshBone Neoplasms
dc.subject.meshChorionic Gonadotropin
dc.subject.meshDepression, Chemical
dc.subject.meshGonadotropin-Releasing Hormone
dc.subject.meshGoserelin
dc.subject.meshHumans
dc.subject.meshLymphatic Metastasis
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPain
dc.subject.meshPelvis
dc.subject.meshProstatic Neoplasms
dc.subject.meshTestosterone
dc.titleTreatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Urology and Medical Oncology, Christie and Withington Hospitals, Manchesteren
dc.identifier.journalLanceten
html.description.abstract9 of 12 patients with advanced metastatic carcinoma of the prostate treated with luteinising-hormone-releasing-hormone (LHRH) analogue ICI 118630 for a mean period of 6 months showed objective evidence of response to treatment. Of 8 patients with bone pain, 7 obtained relief. After 6 weeks of treatment testosterone concentrations were reduced to castrate levels (range less than 2 to 5.5 nmol/l) from a pretreatment mean value of 15.7 nmol/l (range 10.3-24 nmol/l). Basal gonadotropin levels and gonadotropin responses to acute LHRH stimulation were suppressed within 2 weeks of treatment. However, the testosterone response to stimulation with human chorionic gonadotropin was unimpaired 4 weeks after the start of treatment. Therefore suppression of the basal testosterone concentration by ICI 118630 was due to inhibition of pituitary luteinising-hormone secretion rather than direct inhibition of testicular Leydig-cell function. ICI 118630 offers an alternative treatment to orchidectomy and oestrogen therapy.


This item appears in the following Collection(s)

Show simple item record